AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32232597
Drug: Caffeine-containing supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine-containing supplement (200 mg caffeine, 1600 mg β-alanine, 1000 mg quercetin) taken 35 minutes before exercise
Trial: 32232740
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) in combination with methotrexate (MTX)
Trial: 32232817
Drug: Palivizumab administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palivizumab administration during RSV season
Trial: 32233741
Drug: No antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antihypertensive treatment
Trial: 32234475
Drug: Mannose receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannose receptor (MR) deficiency
Trial: 32234848
Drug: Dendritic cell
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic cell (DC)-based immunotherapy
Trial: 32236406
Drug: Isavuconazole (ISAV)
RxNorm normalized name: isavuconazole
DrugBank: Isavuconazole (DB11633)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isavuconazole (ISAV) as primary antifungal prophylaxis (PAP)
Trial: 32236525
Drug: Subcutaneous injections
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of urinary-derived human chorionic gonadotropin (uhCG) in addition to standard immunosuppression
Trial: 32236861
Drug: Missense variant
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Missense variant rs17117699 in OMA1 in group without β-blocker use
Trial: 32236861
Drug: Missense variant
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Missense variant rs17117699 in OMA1 in group with β-blocker use
Trial: 32236861
Drug: Functional analysis
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional analysis of rs17117699-G allele
Trial: 32238343
Drug: mDASHNa-CC app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: mDASHNa-CC app
Trial: 32238515
Drug: Tacrolimus maintenance
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus maintenance therapy
Trial: 32238921
Drug: MRX34 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRX34 with oral dexamethasone premedication, given intravenously daily for 5 days in 3-week cycles.
Trial: 32238921
Drug: MRX34 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MRX34 treatment with dexamethasone premedication
Trial: 32239971
Drug: e-Device (ava®)
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: e-Device (ava®) for self-injection of certolizumab pegol (CZP)
Trial: 32240454
Drug: Trastuzumab SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab SC administered at home by a healthcare professional (HCP)
Trial: 32240454
Drug: Trastuzumab SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab SC administered at home
Trial: 32240629
Drug: Once-weekly rifapentine
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-weekly rifapentine (900 mg) plus isoniazid (900 mg) for 12 weeks
Trial: 32240629
Drug: Dolutegravir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir (50 mg daily) for 8 weeks prior to rifapentine-isoniazid
Trial: 32240793
Drug: CC-90010 (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-90010 (45 mg, 4 days on/24 days off)
Trial: 32240793
Drug: CC-90010 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-90010 (various doses)
Trial: 32240796
Drug: Capmatinib 400
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capmatinib 400 mg (tablets) or 600 mg (capsules) b.i.d.
Trial: 32241317
Drug: Preparation for
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation for end of life factors (knowledge of dementia, social support, feeling supported by healthcare providers, formalized end of life documents, end-of-life discussions)
Trial: 32241904
Drug: Microbiota from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microbiota from patients with ESRD transplanted to renal injured germ-free mice or antibiotic-treated rats
Trial: 32242035
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity extracorporeal low energy shock wave therapy (LiESWT)
Trial: 32242358
Drug: KTE-X19 CAR
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KTE-X19 CAR T-cell therapy
Trial: 32243960
Drug: NS5A-containing DAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NS5A-containing DAA therapy
Trial: 32244368
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose of unfractionated heparin (UFH)
Trial: 32245502
Drug: Bispecific CAR
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bispecific CAR T cell therapy targeting CD19 and CD22
Trial: 32246968
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus for atopic dermatitis (used for ≥6 weeks)
Trial: 32247041
Drug: Quadrivalent human
RxNorm normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent human papillomavirus (qHPV) vaccine
Trial: 32247206
Drug: Extreme hypofractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extreme hypofractionated doses of 35 Gy in 5 weekly fractions to the whole prostate gland with an integrated boost up to 50 Gy to the mpMRI-defined tumour(s)
Trial: 32248659
Drug: Ustekinumab (UST)
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab (UST) 90 mg subcutaneously at baseline and at weeks 4, 12, 20, 28, 36, and 44, combined with a 24-week prednisone taper.
Trial: 32249038
Drug: PRIMA wireless
RxNorm normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRIMA wireless photovoltaic retinal implant
Trial: 32249170
Drug: Non-Drug-Coated Balloon
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Drug-Coated Balloon (non-DCB)
Trial: 32249171
Drug: Certification to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Certification to prescribe and place subdermal contraceptive implants
Trial: 32250517
Drug: Apatinib 500
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 500 mg single-agent
Trial: 32251060
Drug: Subcutaneous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous tocilizumab (TCZ) 162 mg/wk in combination with csDMARDs for 24 weeks
Trial: 32251060
Drug: Subcutaneous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous tocilizumab (TCZ) monotherapy continued until week 52 for patients who achieved remission at week 24
Trial: 32251060
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with csDMARDs
Trial: 32251621
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg intravenously every 2 weeks (Cohort 1: PD-L1 expression at least 1%)
Trial: 32251621
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg intravenously every 2 weeks (Cohort 2: PD-L1 less than 1% or unevaluable)
Trial: 32252538
Drug: Stanford Accelerated
RxNorm normalized name: Stangard
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) - 50 iTBS sessions, 1,800 pulses per session, delivered as 10 daily sessions over 5 consecutive days at 90% resting motor threshold.
Trial: 32252720
Drug: Repetitive transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive transcranial magnetic stimulation (rTMS) treatment for CUD, duration: 90 days, targeted at the left dorsolateral prefrontal cortex.
Trial: 32252720
Drug: Repetitive transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive transcranial magnetic stimulation (rTMS) treatment for CUD.
Trial: 32252781
Drug: Adjuvant radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant radiotherapy alone or in combination with chemotherapy
Trial: 32252781
Drug: Adjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment (radiotherapy or chemotherapy)
Trial: 32253717
Drug: Conivaptan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conivaptan (20 mg) administered every 12 hours for 2 days along with standard ICH management
Trial: 32256049
Drug: Camrelizumab 1
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab 1 mg/kg, 3 mg/kg, 6 mg/kg, and 10 mg/kg every 2 weeks (dose-escalation phase)
Trial: 32256049
Drug: Camrelizumab 200
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab 200 mg or 600 mg every 4 weeks (dose-expansion phase)
Trial: 32256049
Drug: Camrelizumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab (all doses)
Trial: 32256115
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acalabrutinib and obinutuzumab
Trial: 32256270
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg caffeine plus 200 mg chlorogenic acid (CFCA)
Trial: 32256270
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg caffeine plus 200 mg placebo (starch) (CFPL)
Trial: 32256270
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg chlorogenic acid plus 200 mg placebo (CAPL)
Trial: 32256270
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg placebo plus 200 mg placebo (PLPL)
Trial: 32256610
Drug: Deciduous dental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deciduous dental pulp stem cells (DDPSC) associated with hydroxyapatite-collagen sponge (Bio-Oss Collagen® 250 mg, Geistlich)
Trial: 32258591
Drug: Oculomotor and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oculomotor and gaze stability exercises applied at home twice a day for three weeks
Trial: 32258956
Drug: Testosterone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (200 mg testosterone enanthate weekly)
Trial: 32264715
Drug: iVAS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iVAS therapy
Trial: 32264726
Drug: FF-10501-01 (IMPDH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF-10501-01 (IMPDH inhibitor)
Trial: 32265627
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of autologous bone marrow mononuclear cells (BMMCs)
Trial: 32266800
Drug: Progestin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestin treatment regimens (oral medroxyprogesterone acetate (MPA) 10 mg/day for 14 days per cycle, continuous MPA 10 mg/day, levonorgestrel-releasing intrauterine system (LNG-IUS))
Trial: 32267227
Drug: Mandibular advancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular advancement device (MAD) treatment at a fixed 75% degree of maximal protrusion
Trial: 34608859
Drug: Mandibular advancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular advancement device (MAD) treatment
Trial: 32267967
Drug: EE4A chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE4A chemotherapy
Trial: 32268821
Drug: Leflunomide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflunomide (20 mg and 40 mg)
Trial: 32268821
Drug: Leflunomide (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflunomide (60 mg)
Trial: 32268821
Drug: Leflunomide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflunomide (all doses)
Trial: 32269146
Drug: Neoadjuvant PROSTVAC
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant PROSTVAC vaccine
Trial: 32270053
Drug: simeprevir 150
RxNorm normalized name: simeprevir 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simeprevir 150 mg, daclatasvir 60 mg, sofosbuvir 400 mg once-daily for 12 weeks
Trial: 32270056
Drug: Elbasvir/grazoprevir once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elbasvir/grazoprevir once-daily for 12 weeks
Trial: 32270313
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 327 MBq (range 299-399 MBq) of folate receptor alpha-targeted agent
Trial: 32271353
Drug: Durvalumab (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (1500 mg every 4 weeks) until disease progression or unacceptable toxic effects
Trial: 32271899
Drug: Tisagenlecleucel infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tisagenlecleucel infusion with tocilizumab
Trial: 32272183
Drug: Intensity modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity modulated radiation therapy (IMRT) with CTVp1 (60 Gy in 30 fractions)
Trial: 32272183
Drug: Intensity modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity modulated radiation therapy (IMRT) with CTVp2 (54 Gy in 30 fractions)
Trial: 32272183
Drug: Intensity modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity modulated radiation therapy (IMRT) with CTVp1 and CTVp2
Trial: 32272514
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) 50mg subcutaneous (SC) twice weekly for 12 weeks, followed by ETN 50mg SC once weekly for an additional 12 weeks.
Trial: 32272921
Drug: Inhaled corticosteroid/long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid/long-acting β agonist (ICS/LABA)
Trial: 32273476
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (BV) 1.8 mg/kg on day 1, and DHAP (dexamethasone 40mg days 1-4, cisplatin 100mg/m2; day 1, cytarabine 2x2g/m2; day 2)
Trial: 32274381
Drug: YH4808 (potassium-competitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 (potassium-competitive acid blocker); specific dosage and duration not mentioned.
Trial: 32274381
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and clarithromycin; specific dosages and duration not mentioned.
Trial: 32274380
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) of gemigliptin/metformin sustained release 25/500 mg
Trial: 32274380
Drug: Loose combination
RxNorm normalized name: loose wheat smut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loose combination of gemigliptin 50 mg and metformin extended release (XR) 500 mg
Trial: 32274897
Drug: Overfeeding (additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overfeeding (additional 600 kcal, 30 g protein, 72 g carbohydrate, and 21 g fat) in CTs
Trial: 32278280
Drug: DEB-TACE using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEB-TACE using tightly calibrated 100-μm microspheres loaded with 50 mg of doxorubicin per millilitre
Trial: 32278280
Drug: Doxorubicin dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin dose
Trial: 32278621
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy (200-mg run-in dose followed by eight cycles of pembrolizumab with a taxane with or without carboplatin for 12 weeks, then doxorubicin and cyclophosphamide for an additional 12 weeks)
Trial: 32279228
Drug: Bosutinib 400
RxNorm normalized name: bosutinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 400 mg once daily (QD)
Trial: 32279360
Drug: Chair resistance
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chair resistance training (RT) with sandbags/dumbbells, twice a week for 3 months
Trial: 32279702
Drug: Therapeutic decisions
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic decisions (PAP vs conservative treatment)
Trial: 32280268
Drug: Morphine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine group (M): received ultrasound-guided serratus anterior plane block with 20 mL of bupivacaine hydrochloride 0.25% plus 10 mg morphine sulfate
Trial: 32280268
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C): received ultrasound-guided serratus anterior plane block with 20 mL of bupivacaine hydrochloride 0.25%
Trial: 32280375
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of prebiotics and probiotics
Trial: 32280529
Drug: Cataract surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cataract surgery in eyes with posterior capsule defect (PCD)
Trial: 32280529
Drug: Cataract surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cataract surgery in eyes without posterior capsule abnormalities (PCA)
Trial: 32282545
Drug: Laboratory preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laboratory preparation process
Trial: 32283645
Drug: Probiotic multi-strain
RxNorm normalized name: Bacillus subtilis/Lactobacillus Sporogenes/Probiotic Cultures 1 BILLION CFU Oral Tablet, Chewable [DIGESTIVE ADVANTAGE PROBIOTIC MULTI-STRAIN ULTRA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic multi-strain formulation
Trial: 32284384
Drug: Gepotidacin (GSK2140944),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepotidacin (GSK2140944), dosage and duration not specified
Trial: 32285088
Drug: Mindful yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindful yoga intervention (1 hour, thrice weekly for 3 months)
Trial: 32285998
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) at 15 mg/kg/day during radiation therapy and continued post-radiation, followed by bevacizumab at 10 mg/kg biweekly after radiation.
Trial: 32285998
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) and bevacizumab after radiation therapy.
Trial: 32286195
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT screening for lung cancer using Lung-RADS categories 3 or 4.
Trial: 32287122
Drug: Machine-learning algorithm
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine-learning algorithm (SVM) using intranasal pressure sensor
Trial: 32287128
Drug: Deep learning
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep learning model trained on sleep EEG data using dexmedetomidine as a prototype drug
Trial: 32289161
Drug: Albuminuria (ACR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuminuria (ACR ≥30 mg/g) for ≥2 annual measurements classified as persistent albuminuria (PA).
Trial: 32290838
Drug: Triptorelin SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin SR (11.25 mg) plus Tibolone (2.5 mg)
Trial: 32293449
Drug: NT-proBNP >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP > 88.64 pg/mL
Trial: 32293449
Drug: NT-proBNP ≤
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP ≤ 88.64 pg/mL
Trial: 32294561
Drug: IncobotulinumtoxinA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IncobotulinumtoxinA treatment for pes equinovarus
Trial: 32295504
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose level ≤140 mg/dL
Trial: 38160756
Drug: Pitavastatin calcium
RxNorm normalized name: PITAVASTATIN CALCIUM
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin calcium (4 mg/day) for 180 days
Trial: 32296711
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation, dosage not specified, duration not specified